Associated Genetic Biomarkers
ERBB2 G778_P780dup is present in 0.07% of AACR GENIE cases, with lung adenocarcinoma and breast invasive ductal carcinoma having the greatest prevalence .
ERBB2 G778_P780dup serves as an inclusion eligibility criterion in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 G778_P780dup as an inclusion criterion, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open).
Trials with ERBB2 G778_P780dup in the inclusion eligibility criteria most commonly target breast carcinoma, colorectal adenocarcinoma, and malignant solid tumor .
Neratinib, bdtx-189, cetuximab, and trastuzumab are the most frequent therapies in trials with ERBB2 G778_P780dup as an inclusion criteria .
Significance of ERBB2 G778_P780dup in Diseases
Breast Carcinoma +
ERBB2 is altered in 12.77% of breast carcinoma patients with ERBB2 G778_P780dup present in 0.2% of all breast carcinoma patients .
ERBB2 G778_P780dup is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 G778_P780dup and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
Malignant Solid Tumor +
ERBB2 is altered in 4.96% of malignant solid tumor patients with ERBB2 G778_P780dup present in 0.07% of all malignant solid tumor patients .
ERBB2 G778_P780dup is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 G778_P780dup and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.